Interestingly, of the three tumor subtypes, CMMRD-associated hematologic malignancies have the lowest TMB and lack enrichment for TP53, RAS-MAPK pathway and ATRX mutations, which are noted in CMMRD-associated solid tumors. This evidence concerns the gene TP53 and neoplasm.